Notably, sorafenib has been shown to increase IL-15 production in mutant FLT3-ITD leukemia cells, increase IFN-γ production, and lead to metabolic reprograming of leukemia reactive T cells among relapsed patients post-allo-HCT who respond to treatment (83). This evidence concerns the gene IFNG and leukemia.